Issues in neuroprotection clinical trials in Parkinson's disease

Neurology

Volumn 66, Issue 10 SUPPL. 4, 2006, Pages

  Kieburtz, Karl ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPROTECTIVE AGENT;

CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG EFFICACY; GENE MUTATION; HIGH RISK POPULATION; HUMAN; NEUROIMAGING; NEUROPROTECTION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RISK FACTOR; ARTICLE; CLASSIFICATION; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; METHODOLOGY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; TREATMENT OUTCOME;

CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; NEUROPROTECTIVE AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 33744981624     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.66.10_suppl_4.s50     Document Type: Review

References (0)